Most patients with non–small cell lung cancer (NSCLC) are diagnosed with advanced cancer. These guidelines only include information about stage IV NSCLC. Patients with widespread metastatic disease (stage IV) are candidates for systemic therapy, clinical trials, and/or palliative treatment. The goal is to identify patients with metastatic disease before initiating aggressive treatment, thus sparing these patients from unnecessary futile treatment. If metastatic disease is discovered during surgery, then extensive surgery is often aborted. Decisions about treatment should be based on multidisciplinary discussion.

  • 1

    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:1029.

  • 2

    Spiro SG, Gould MK, Colice GL. Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 2007;132:149S160S.

    • Search Google Scholar
    • Export Citation
  • 3

    Silvestri GA, Gould MK, Margolis ML. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 2007;132:178S201S.

    • Search Google Scholar
    • Export Citation
  • 4

    De Wever W, Vankan Y, Stroobants S, Verschakelen J. Detection of extrapulmonary lesions with integrated PET/CT in the staging of lung cancer. Eur Respir J 2007;29:9951002.

    • Search Google Scholar
    • Export Citation
  • 5

    The Health Consequences of Smoking: A Report of the Surgeon General. (ed 2010/07/30). Atlanta, GA: U.S. Department of Health and Human Services. Centers for Disease Control and Prevention (US); 2004.

    • Search Google Scholar
    • Export Citation
  • 6

    Secretan B, Straif K, Baan R. A review of human carcinogens—Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol 2009;10:10331034.

    • Search Google Scholar
    • Export Citation
  • 7

    Doll R, Peto R. Mortality in relation to smoking: 20 years’ observations on male British doctors. Br Med J 1976;2:15251536.

  • 8

    Taylor R, Najafi F, Dobson A. Meta-analysis of studies of passive smoking and lung cancer: effects of study type and continent. Int J Epidemiol 2007;36:10481059.

    • Search Google Scholar
    • Export Citation
  • 9

    The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General. (ed 2010/07/30). Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2006.

    • Search Google Scholar
    • Export Citation
  • 10

    Hackshaw AK, Law MR, Wald NJ. The accumulated evidence on lung cancer and environmental tobacco smoke. BMJ 1997;315:980988.

  • 11

    Wald NJ, Nanchahal K, Thompson SG, Cuckle HS. Does breathing other people’s tobacco smoke cause lung cancer? Br Med J (Clin Res Ed) 1986;293:12171222.

    • Search Google Scholar
    • Export Citation
  • 12

    Aubin HJ, Bobak A, Britton JR. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax 2008;63:717724.

    • Search Google Scholar
    • Export Citation
  • 13

    Jorenby DE, Hays JT, Rigotti NA. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006;296:5663.

    • Search Google Scholar
    • Export Citation
  • 14

    Gonzales D, Rennard SI, Nides M. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006;296:4755.

    • Search Google Scholar
    • Export Citation
  • 15

    Garrison GD, Dugan SE. Varenicline: a first-line treatment option for smoking cessation. Clin Ther 2009;31:463491.

  • 16

    Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2011:CD006103.

  • 17

    Xi ZX. Preclinical pharmacology, efficacy and safety of varenicline in smoking cessation and clinical utility in high risk patients. Drug Healthc Patient Saf 2010;2010:3948.

    • Search Google Scholar
    • Export Citation
  • 18

    Hays JT, Ebbert JO. Adverse effects and tolerability of medications for the treatment of tobacco use and dependence. Drugs 2010;70:23572372.

    • Search Google Scholar
    • Export Citation
  • 19

    Carney DN. Lung cancer—time to move on from chemotherapy. N Engl J Med 2002;346:126128.

  • 20

    Chute JP, Chen T, Feigal E. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999;17:17941801.

    • Search Google Scholar
    • Export Citation
  • 21

    Henschke CI, McCauley DI, Yankelevitz DF. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 1999;354:99105.

    • Search Google Scholar
    • Export Citation
  • 22

    Henschke CI, Naidich DP, Yankelevitz DF. Early Lung Cancer Action Project: initial findings on repeat screenings. Cancer 2001;92:153159.

  • 23

    Kaneko M, Kusumoto M, Kobayashi T. Computed tomography screening for lung carcinoma in Japan. Cancer 2000;89:24852488.

  • 24

    The National Lung Screening Trial: overview and study design. Radiology 2011;258:243253.

  • 25

    Aberle DR, Adams AM, Berg CD. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395409.

  • 26

    Aberle DR, Adams AM, Berg CD. Baseline characteristics of participants in the randomized national lung screening trial. J Natl Cancer Inst 2010;102:17711779.

    • Search Google Scholar
    • Export Citation
  • 27

    Wood DE, Eapen GA, Ettinger DS. Lung Cancer Screening. J Natl Compr Canc Netw 2012;110:240265. To view the most recent version of these guidelines, visit NCCN.org.

    • Search Google Scholar
    • Export Citation
  • 28

    Henschke CI, Yankelevitz DF, Libby DM. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 2006;355:17631771.

    • Search Google Scholar
    • Export Citation
  • 29

    Travis WD, Brambilla E, Noguchi M. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6:244285.

    • Search Google Scholar
    • Export Citation
  • 30

    Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1986;4:702709.

    • Search Google Scholar
    • Export Citation
  • 31

    Cooper WA, O’Toole S, Boyer M. What’s new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements. Pathology 2011;43:103115.

    • Search Google Scholar
    • Export Citation
  • 32

    Fossella FV, Putnam JB, Komaki R, eds. Lung Cancer. M.D. Anderson Cancer Care Series. New York: Springer; 2003.

  • 33

    Eberhard DA, Johnson BE, Amler LC. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:59005909.

    • Search Google Scholar
    • Export Citation
  • 34

    Cappuzzo F, Ligorio C, Toschi L. EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2007;2:423429.

    • Search Google Scholar
    • Export Citation
  • 35

    Kwak EL, Bang YJ, Camidge DR. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:16931703.

  • 36

    Travis WD. Pathology and genetics of tumours of the lung, pleura, thymus and heart Lyon: IARC Press; 2004.

  • 37

    Rekhtman N, Ang DC, Sima CS. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol 2011;24:13481359.

    • Search Google Scholar
    • Export Citation
  • 38

    Mukhopadhyay S, Katzenstein AL. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol 2011;35:1525.

    • Search Google Scholar
    • Export Citation
  • 39

    Terry J, Leung S, Laskin J. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Am J Surg Pathol 2010;34:18051811.

    • Search Google Scholar
    • Export Citation
  • 40

    Husain AN, Colby TV, Ordonez NG. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2009;133:13171331.

    • Search Google Scholar
    • Export Citation
  • 41

    King JE, Thatcher N, Pickering CA, Hasleton PS. Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data. Histopathology 2006;48:223232.

    • Search Google Scholar
    • Export Citation
  • 42

    Ordonez NG. D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum Pathol 2005;36:372380.

    • Search Google Scholar
    • Export Citation
  • 43

    Ordonez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol 2003;27:10311051.

    • Search Google Scholar
    • Export Citation
  • 44

    Ordonez NG. Thyroid transcription factor-1 is a marker of lung and thyroid carcinomas. Adv Anat Pathol 2000;7:123127.

  • 45

    Rivera MP, Mehta AC. Initial diagnosis of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132:131S148S.

    • Search Google Scholar
    • Export Citation
  • 46

    Tan D, Zander DS. Immunohistochemistry for assessment of pulmonary and pleural neoplasms: a review and update. Int J Clin Exp Pathol 2008;1:1931.

    • Search Google Scholar
    • Export Citation
  • 47

    Zhang H, Liu J, Cagle PT. Distinction of pulmonary small cell carcinoma from poorly differentiated squamous cell carcinoma: an immunohistochemical approach. Mod Pathol 2005;18:111118.

    • Search Google Scholar
    • Export Citation
  • 48

    Guinee DG Jr, Fishback NF, Koss MN. The spectrum of immunohistochemical staining of small-cell lung carcinoma in specimens from transbronchial and open-lung biopsies. Am J Clin Pathol 1994;102:406414.

    • Search Google Scholar
    • Export Citation
  • 49

    Du L, Schageman JJ, Irnov. MicroRNA expression distinguishes SCLC from NSCLC lung tumor cells and suggests a possible pathological relationship between SCLCs and NSCLCs. J Exp Clin Cancer Res 2010;29:75.

    • Search Google Scholar
    • Export Citation
  • 50

    Greene FL, Page DL, Fleming ID. AJCC Cancer Staging Manual, 6th ed. New York: Springer-Verlag; 2002.

  • 51

    Mountain CF. A new international staging system for lung cancer. Chest 1986;89:225S233S.

  • 52

    Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:17101717.

  • 53

    Mountain CF. Staging classification of lung cancer. A critical evaluation. Clin Chest Med 2002;23:103121.

  • 54

    Goldstraw P, Crowley J, Chansky K. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2:706714.

    • Search Google Scholar
    • Export Citation
  • 55

    Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest 2009;136:260271.

  • 56

    Edge SB, Byrd DR, Compton CC. AJCC Cancer Staging Manual, 7th ed. New York: Springer; 2010.

  • 57

    Rami-Porta R, Bolejack V, Goldstraw P. The new tumor, node, and metastasis staging system. Semin Respir Crit Care Med 2011;32:4451.

  • 58

    Rami-Porta R, Crowley JJ, Goldstraw P. The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg 2009;15:49.

  • 59

    Tsao MS, Sakurada A, Cutz JC. Erlotinib in lung cancer–molecular and clinical predictors of outcome. N Engl J Med 2005;353:133144.

  • 60

    Miller VA, Riely GJ, Zakowski MF. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 2008;26:14721478.

    • Search Google Scholar
    • Export Citation
  • 61

    Sequist LV, Martins RG, Spigel D. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008;26:24422449.

    • Search Google Scholar
    • Export Citation
  • 62

    Shaw AT, Forcione DG, Digumarthy SR, Iafrate AJ. Case records of the Massachusetts General Hospital. Case 21-2011. A 31-year-old man with ALK-positive adenocarcinoma of the lung. N Engl J Med 2011;365:158167.

    • Search Google Scholar
    • Export Citation
  • 63

    Shaw AT, Yeap BY, Mino-Kenudson M. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009;27:42474253.

    • Search Google Scholar
    • Export Citation
  • 64

    Dias-Santagata D, Akhavanfard S, David SS. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med 2010;2:146158.

    • Search Google Scholar
    • Export Citation
  • 65

    Paik PK, Arcila ME, Fara M. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 2011;29:20462051.

    • Search Google Scholar
    • Export Citation
  • 66

    Hirsch FR, Bunn PA Jr. EGFR testing in lung cancer is ready for prime time. Lancet Oncol 2009;10:432433.

  • 67

    Riely GJ, Politi KA, Miller VA, Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 2006;12:72327241.

    • Search Google Scholar
    • Export Citation
  • 68

    Pao W, Miller VA, Politi KA. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.

    • Search Google Scholar
    • Export Citation
  • 69

    Kosaka T, Yatabe Y, Endoh H. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 2006;12:57645769.

    • Search Google Scholar
    • Export Citation
  • 70

    Onitsuka T, Uramoto H, Nose N. Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. Lung Cancer 2010;68:198203.

    • Search Google Scholar
    • Export Citation
  • 71

    Han SW, Kim TY, Jeon YK. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin Cancer Res 2006;12:25382544.

    • Search Google Scholar
    • Export Citation
  • 72

    Dacic S. EGFR assays in lung cancer. Adv Anat Pathol 2008;15:241247.

  • 73

    Sholl LM, Xiao Y, Joshi V. EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry. Am J Clin Pathol 2010;133:922934.

    • Search Google Scholar
    • Export Citation
  • 74

    Eberhard DA, Giaccone G, Johnson BE. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol 2008;26:983994.

    • Search Google Scholar
    • Export Citation
  • 75

    Pao W, Ladanyi M. Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res 2007;13:49544955.

    • Search Google Scholar
    • Export Citation
  • 76

    Shepherd FA, Tsao MS. Epidermal growth factor receptor biomarkers in non-small-cell lung cancer: a riddle, wrapped in a mystery, inside an enigma. J Clin Oncol 2010;28:903905.

    • Search Google Scholar
    • Export Citation
  • 77

    Lynch TJ, Bell DW, Sordella R. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:21292139.

    • Search Google Scholar
    • Export Citation
  • 78

    Paez JG, Janne PA, Lee JC. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:14971500.

    • Search Google Scholar
    • Export Citation
  • 79

    Mitsudomi T, Morita S, Yatabe Y. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121128.

    • Search Google Scholar
    • Export Citation
  • 80

    Maemondo M, Inoue A, Kobayashi K. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:23802388.

    • Search Google Scholar
    • Export Citation
  • 81

    Zhou C, Wu YL, Chen G. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735742.

    • Search Google Scholar
    • Export Citation
  • 82

    Zhou C, Wu YL, Chen G. Updated efficacy and quality-of-life (QoL) analyses in OPTIMAL, a phase III, randomized, open-label study of first-line erlotinib versus gemcitabine/carboplatin in patients with EGFR-activating mutation-positive (EGFR Act Mut+) advanced non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2011;29(Suppl 15):Abstract 7520.

    • Search Google Scholar
    • Export Citation
  • 83

    Rosell R, Gervais R, Vergnenegre A. Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial [abstract]. J Clin Oncol 2011;29(Suppl 15):Abstract 7503.

    • Search Google Scholar
    • Export Citation
  • 84

    Takahashi T, Sonobe M, Kobayashi M. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol 2010;17:889897.

    • Search Google Scholar
    • Export Citation
  • 85

    Kim H, Yoo SB, Choe JY. Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression. J Thorac Oncol 2011;6:13591366.

    • Search Google Scholar
    • Export Citation
  • 86

    Rodig SJ, Mino-Kenudson M, Dacic S. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009;15:52165223.

    • Search Google Scholar
    • Export Citation
  • 87

    Mino-Kenudson M, Chirieac LR, Law K. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 2010;16:15611571.

    • Search Google Scholar
    • Export Citation
  • 88

    Crino L, Kim D, Riely GJ. Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005 [abstract]. J Clin Oncol 2011;29(Suppl 15):Abstract 7514.

    • Search Google Scholar
    • Export Citation
  • 89

    Camidge DR, Bang Y, Kwak EL. Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2011;29(Suppl 15):Abstract 2501.

    • Search Google Scholar
    • Export Citation
  • 90

    Rodig SJ, Shapiro GI. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. Curr Opin Investig Drugs 2010;11:14771490.

    • Search Google Scholar
    • Export Citation
  • 91

    Shaw AT, Yeap BY, Solomon BJ. Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls [abstract]. J Clin Oncol 2011;29(Suppl 15):Abstract 7507.

    • Search Google Scholar
    • Export Citation
  • 92

    Choi YL, Soda M, Yamashita Y. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010;363:17341739.

  • 93

    Katayama R, Khan TM, Benes C. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A 2011;108:75357540.

    • Search Google Scholar
    • Export Citation
  • 94

    Sequist LV, Gettinger S, Senzer NN. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol 2010;28:49534960. A

    • Search Google Scholar
    • Export Citation
  • 95

    Zhang S, Wang F, Keats F. AP26113, a potent ALK inhibitor, overcomes mutations in EML4-ALK that confer resistance to PF-02341066 (PF1066) [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; April 17–21, 2010; Washington, DC. Abstract LB-298.

    • Search Google Scholar
    • Export Citation
  • 96

    Cheng M, Ott GR. Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neuroblastoma. Anticancer Agents Med Chem 2010;10:236249.

    • Search Google Scholar
    • Export Citation
  • 97

    Socinski MA, Crowell R, Hensing TE. Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132:277S289S.

    • Search Google Scholar
    • Export Citation
  • 98

    Azzoli CG, Baker S Jr, Temin S. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009:27:62516266.

    • Search Google Scholar
    • Export Citation
  • 99

    NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008;26:46174625.

    • Search Google Scholar
    • Export Citation
  • 100

    Souquet PJ, Chauvin F, Boissel JP. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet 1993;342:1921.

  • 101

    Temel JS, Greer JA, Muzikansky A. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010;363:733742.

    • Search Google Scholar
    • Export Citation
  • 102

    Magilligan DJ Jr, Duvernoy C, Malik G. Surgical approach to lung cancer with solitary cerebral metastasis: twenty-five years’ experience. Ann Thorac Surg 1986;42:360364.

    • Search Google Scholar
    • Export Citation
  • 103

    Azzoli CG, Temin S, Aliff T. 2011 Focused update of 2009 American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2011;29:38253831.

    • Search Google Scholar
    • Export Citation
  • 104

    Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899909.

    • Search Google Scholar
    • Export Citation
  • 105

    Ohe Y, Ohashi Y, Kubota K. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2007;18:317323.

    • Search Google Scholar
    • Export Citation
  • 106

    Fossella F, Pereira JR, von Pawel J. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003;21:30163024.

    • Search Google Scholar
    • Export Citation
  • 107

    Smit EF, van Meerbeeck JP, Lianes P. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group—EORTC 08975. J Clin Oncol 2003;21:39093917.

    • Search Google Scholar
    • Export Citation
  • 108

    Zatloukal P, Petruzelka L, Zemanova M. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 2004;46:8798.

    • Search Google Scholar
    • Export Citation
  • 109

    Scagliotti GV, Parikh P, von Pawel J. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:35433551. A

    • Search Google Scholar
    • Export Citation
  • 110

    Kelly K, Crowley J, Bunn PA Jr. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non–small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001;19:32103218.

    • Search Google Scholar
    • Export Citation
  • 111

    Schiller JH, Harrington D, Belani CP. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:9298.

    • Search Google Scholar
    • Export Citation
  • 112

    Danson S, Middleton MR, O’Byrne KJ. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer 2003;98:542553.

    • Search Google Scholar
    • Export Citation
  • 113

    Booton R, Lorigan P, Anderson H. A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1). Ann Oncol 2006;17:11111119.

    • Search Google Scholar
    • Export Citation
  • 114

    Gronberg BH, Bremnes RM, Flotten O. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:32173224.

    • Search Google Scholar
    • Export Citation
  • 115

    Greco FA, Spigel DR, Kuzur ME. Paclitaxel/carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Network. Clin Lung Cancer 2007;8:483487.

    • Search Google Scholar
    • Export Citation
  • 116

    Herbst RS, Khuri FR, Lu C. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. Cancer 2002;95:340353.

    • Search Google Scholar
    • Export Citation
  • 117

    Pujol JL, Breton JL, Gervais R. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol 2005;16:602610.

    • Search Google Scholar
    • Export Citation
  • 118

    Rizvi NA, Riely GJ, Azzoli CG. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. J Clin Oncol 2008;26:639643.

    • Search Google Scholar
    • Export Citation
  • 119

    Green MR, Manikhas GM, Orlov S. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 2006;17:12631268.

    • Search Google Scholar
    • Export Citation
  • 120

    Sandler AB, Johnson DH, Herbst RS. Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer. Clin Cancer Res 2004;10:4258s4262s.

    • Search Google Scholar
    • Export Citation
  • 121

    Giaccone G. Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol 2005;23:32353242.

  • 122

    Sandler A, Gray R, Perry MC. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:25422550.

    • Search Google Scholar
    • Export Citation
  • 123

    Sequist LV, Joshi VA, Janne PA. Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist 2007;12:9098.

    • Search Google Scholar
    • Export Citation
  • 124

    Mok TS, Wu YL, Thongprasert S. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947957.

  • 125

    Inoue A, Kobayashi K, Usui K. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 2009;27:13941400.

    • Search Google Scholar
    • Export Citation
  • 126

    Jackman DM, Miller VA, Cioffredi LA. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 2009;15:52675273.

    • Search Google Scholar
    • Export Citation
  • 127

    Gridelli C, Ciardiello F, Feld R. International multicenter randomized phase III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by second-line E in advanced non-small cell lung cancer (aNSCLC): the TORCH trial [abstract]. J Clin Oncol 2010;28(Suppl 15):Abstract 7508.

    • Search Google Scholar
    • Export Citation
  • 128

    Keedy VL, Temin S, Somerfield MR. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 2011;29:21212127.

    • Search Google Scholar
    • Export Citation
  • 129

    Felip E, Gridelli C, Baas P. Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Ann Oncol 2011;22:15071519.

    • Search Google Scholar
    • Export Citation
  • 130

    Pirker R, Pereira JR, Szczesna A. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009;373:15251531.

    • Search Google Scholar
    • Export Citation
  • 131

    Patel JD, Hensing TA, Rademaker A. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 2009;27:32843289.

    • Search Google Scholar
    • Export Citation
  • 132

    Nadler E, Yu E, Ravelo A. Bevacizumab treatment to progression after chemotherapy: outcomes from a U.S. community practice network. Oncologist 2011;16:486496.

    • Search Google Scholar
    • Export Citation
  • 133

    Paz-Ares LG, De Marinis F, Dediu M. PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2011;29(Suppl 18):Abstract CRA7510.

    • Search Google Scholar
    • Export Citation
  • 134

    Fidias P, Novello S. Strategies for prolonged therapy in patients with advanced non-small-cell lung cancer. J Clin Oncol 2010;28:51165123.

    • Search Google Scholar
    • Export Citation
  • 135

    Stinchcombe TE, Socinski MA. Treatment paradigms for advanced stage non-small cell lung cancer in the era of multiple lines of therapy. J Thorac Oncol 2009;4:243250.

    • Search Google Scholar
    • Export Citation
  • 136

    Fidias P, Novello S. Strategies for prolonged therapy in patients with advanced non-small-cell lung cancer. J Clin Oncol 2010;28:51165123.

    • Search Google Scholar
    • Export Citation
  • 137

    Perol M, Chouaid C, Milleron BJ. Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study [abstract]. J Clin Oncol 2010;28(Suppl 15):Abstract 7507.

    • Search Google Scholar
    • Export Citation
  • 138

    Brodowicz T, Krzakowski M, Zwitter M. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 2006;52:155163.

    • Search Google Scholar
    • Export Citation
  • 139

    Cappuzzo F, Ciuleanu T, Stelmakh L. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521529.

    • Search Google Scholar
    • Export Citation
  • 140

    Ciuleanu T, Brodowicz T, Zielinski C. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:14321440.

    • Search Google Scholar
    • Export Citation
  • 141

    Cohen MH, Cortazar P, Justice R, Pazdur R. Approval summary: pemetrexed maintenance therapy of advanced/metastatic nonsquamous, non-small cell lung cancer (NSCLC). Oncologist 2010;15:13521358.

    • Search Google Scholar
    • Export Citation
  • 142

    Fidias PM, Dakhil SR, Lyss AP. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:591598.

    • Search Google Scholar
    • Export Citation
  • 143

    Janne PA, Wang XF, Socinski MA. Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 [abstract]. J Clin Oncol 2010;28(Suppl 15):Abstract 7503.

    • Search Google Scholar
    • Export Citation
  • 144

    Cohen MH, Johnson JR, Chattopadhyay S. Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC). Oncologist 2010;15:13441351.

    • Search Google Scholar
    • Export Citation
  • 145

    Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. The Lung Cancer Study Group. N Engl J Med 1986;315:13771381.

    • Search Google Scholar
    • Export Citation
  • 146

    Keller SM, Adak S, Wagner H. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med 2000;343:12171222.

    • Search Google Scholar
    • Export Citation
  • 147

    Douillard JY, Rosell R, De Lena M. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial. Int J Radiat Oncol Biol Phys 2008;72:695701.

    • Search Google Scholar
    • Export Citation
  • 148

    Bradley JD, Paulus R, Graham MV. Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group—RTOG 9705. J Clin Oncol 2005;23:34803487.

    • Search Google Scholar
    • Export Citation
  • 149

    Feigenberg SJ, Hanlon AL, Langer C. A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancer. J Thorac Oncol 2007;2:287292.

    • Search Google Scholar
    • Export Citation
  • 150

    Jaklitsch MT, Herndon JE 2nd, DeCamp MM Jr. Nodal downstaging predicts survival following induction chemotherapy for stage IIIA (N2) non-small cell lung cancer in CALGB protocol #8935. J Surg Oncol 2006;94:599606.

    • Search Google Scholar
    • Export Citation
  • 151

    Chow E, Harris K, Fan G. Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol 2007;25:14231436.

  • 152

    Lutz S, Berk L, Chang E. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys 2011;79:965976.

    • Search Google Scholar
    • Export Citation
  • 153

    Cross CK, Berman S, Buswell L. Prospective study of palliative hypofractionated radiotherapy (8.5 Gy x 2) for patients with symptomatic non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004;58:10981105.

    • Search Google Scholar
    • Export Citation
  • 154

    A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Medical Research Council Lung Cancer Working Party. Br J Cancer 1992;65:934941.

    • Search Google Scholar
    • Export Citation
  • 155

    Milano MT, Katz AW, Okunieff P. Patterns of recurrence after curative-intent radiation for oligometastases confined to one organ. Am J Clin Oncol 2010;33:157163.

    • Search Google Scholar
    • Export Citation
  • 156

    Rusthoven KE, Kavanagh BD, Burri SH. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol 2009;27:15791584.

    • Search Google Scholar
    • Export Citation
  • 157

    Salama JK, Chmura SJ, Mehta N. An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease. Clin Cancer Res 2008;14:52555259.

    • Search Google Scholar
    • Export Citation
  • 158

    Dahele M, Senan S. The role of stereotactic ablative radiotherapy for early-stage and oligometastatic non-small cell lung cancer: evidence for changing paradigms. Cancer Res Treat 2011;43:7582.

    • Search Google Scholar
    • Export Citation
  • 159

    Heinzerling JH, Kavanagh B, Timmerman RD. Stereotactic ablative radiation therapy for primary lung tumors. Cancer J 2011;17:2832.

  • 160

    Potters L, Kavanagh B, Galvin JM. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2010;76:326332.

    • Search Google Scholar
    • Export Citation
  • 161

    Salazar OM, Sandhu TS, Lattin PB. Once-weekly, high-dose stereotactic body radiotherapy for lung cancer: 6-year analysis of 60 early-stage, 42 locally advanced, and 7 metastatic lung cancers. Int J Radiat Oncol Biol Phys 2008;72:707715.

    • Search Google Scholar
    • Export Citation
  • 162

    Guckenberger M, Wulf J, Mueller G. Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. Int J Radiat Oncol Biol Phys 2009;74:4754.

    • Search Google Scholar
    • Export Citation
  • 163

    Hadziahmetovic M, Loo BW, Timmerman RD. Stereotactic body radiation therapy (stereotactic ablative radiotherapy) for stage I non-small cell lung cancer—updates of radiobiology, techniques, and clinical outcomes. Discov Med 2010;9:411417.

    • Search Google Scholar
    • Export Citation
  • 164

    Hara R, Itami J, Kondo T. Clinical outcomes of single-fraction stereotactic radiation therapy of lung tumors. Cancer 2006;106:13471352.

  • 165

    Baumann P, Nyman J, Hoyer M. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 2009;27:32903296.

    • Search Google Scholar
    • Export Citation
  • 166

    Fakiris AJ, McGarry RC, Yiannoutsos CT. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys 2009;75:677682.

    • Search Google Scholar
    • Export Citation
  • 167

    Chang JY, Balter PA, Dong L. Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2008;72:967971.

    • Search Google Scholar
    • Export Citation
  • 168

    Takeda A, Sanuki N, Kunieda E. Stereotactic body radiotherapy for primary lung cancer at a dose of 50 Gy total in five fractions to the periphery of the planning target volume calculated using a superposition algorithm. Int J Radiat Oncol Biol Phys 2009;73:442448.

    • Search Google Scholar
    • Export Citation
  • 169

    Stephans KL, Djemil T, Reddy CA. A comparison of two stereotactic body radiation fractionation schedules for medically inoperable stage I non-small cell lung cancer: the Cleveland Clinic experience. J Thorac Oncol 2009;4:976982.

    • Search Google Scholar
    • Export Citation
  • 170

    Jin JY, Kong FM, Chetty IJ. Impact of fraction size on lung radiation toxicity: hypofractionation may be beneficial in dose escalation of radiotherapy for lung cancers. Int J Radiat Oncol Biol Phys 2010;76:782788.

    • Search Google Scholar
    • Export Citation
  • 171

    Onishi H, Shirato H, Nagata Y. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007;2:S94100.

    • Search Google Scholar
    • Export Citation
  • 172

    Hu C, Chang EL, Hassenbusch SJ 3rd. Nonsmall cell lung cancer presenting with synchronous solitary brain metastasis. Cancer 2006;106:19982004.

    • Search Google Scholar
    • Export Citation
  • 173

    Kalkanis SN, Kondziolka D, Gaspar LE. The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010;96:3343.

    • Search Google Scholar
    • Export Citation
  • 174

    Gaspar LE, Mehta MP, Patchell RA. The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010;96:1732.

    • Search Google Scholar
    • Export Citation
  • 175

    Mintz A, Perry J, Spithoff K. Management of single brain metastasis: a practice guideline. Curr Oncol 2007;14:131143.

  • 176

    Patchell RA, Tibbs PA, Walsh JW. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990;322:494500.

    • Search Google Scholar
    • Export Citation
  • 177

    Linskey ME, Andrews DW, Asher AL. The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010;96:4568.

    • Search Google Scholar
    • Export Citation
  • 178

    Aoyama H, Shirato H, Tago M. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006;295:24832491.

    • Search Google Scholar
    • Export Citation
  • 179

    Kim JE, Lee DH, Choi Y. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer 2009;65:351354.

    • Search Google Scholar
    • Export Citation
  • 180

    Olson JJ, Paleologos NA, Gaspar LE. The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics. J Neurooncol 2010;96:115142.

    • Search Google Scholar
    • Export Citation
  • 181

    Mehta MP, Paleologos NA, Mikkelsen T. The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010;96:7183.

    • Search Google Scholar
    • Export Citation
  • 182

    Ammirati M, Cobbs CS, Linskey ME. The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010;96:8596.

    • Search Google Scholar
    • Export Citation
  • 183

    Li J, Bentzen SM, Renschler M, Mehta MP. Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function. J Clin Oncol 2007;25:12601266.

    • Search Google Scholar
    • Export Citation
  • 184

    Aoyama H, Tago M, Kato N. Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys 2007;68:13881395.

    • Search Google Scholar
    • Export Citation
  • 185

    Chang EL, Wefel JS, Hess KR. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 2009;10:10371044.

    • Search Google Scholar
    • Export Citation
  • 186

    Marsh JC, Gielda BT, Herskovic AM, Abrams RA. Cognitive sparing during the administration of whole brain radiotherapy and prophylactic cranial irradiation: current concepts and approaches. J Oncol 2010;2010:198208.

    • Search Google Scholar
    • Export Citation
  • 187

    Gore EM, Bae K, Wong SJ. Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. J Clin Oncol 2011;29:272278.

    • Search Google Scholar
    • Export Citation
  • 188

    Sun A, Bae K, Gore EM. Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis. J Clin Oncol 2011;29:279286.

    • Search Google Scholar
    • Export Citation
  • 189

    Pieterman RM, van Putten JW, Meuzelaar JJ. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000;343:254261.

    • Search Google Scholar
    • Export Citation
  • 190

    Manente P, Vicario G, Piazza F. Does PET/CT modify the therapeutic approach in medical oncology [abstract]? J Clin Oncol 2008;26(Suppl 15):Abstract 17525.

    • Search Google Scholar
    • Export Citation
  • 191

    Maziak DE, Darling GE, Inculet RI. Positron emission tomography in staging early lung cancer: a randomized trial. Ann Intern Med 2009;151:221–228, W-248.

    • Search Google Scholar
    • Export Citation
  • 192

    Fischer B, Lassen U, Mortensen J. Preoperative staging of lung cancer with combined PET-CT. N Engl J Med 2009;361:3239.

  • 193

    De Wever W, Stroobants S, Coolen J, Verschakelen JA. Integrated PET/CT in the staging of nonsmall cell lung cancer: technical aspects and clinical integration. Eur Respir J 2009;33:201212.

    • Search Google Scholar
    • Export Citation
  • 194

    Vilmann P, Krasnik M, Larsen SS. Transesophageal endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) and endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) biopsy: a combined approach in the evaluation of mediastinal lesions. Endoscopy 2005;37:833839.

    • Search Google Scholar
    • Export Citation
  • 195

    Yasufuku K, Nakajima T, Motoori K. Comparison of endobronchial ultrasound, positron emission tomography, and CT for lymph node staging of lung cancer. Chest 2006;130:710718.

    • Search Google Scholar
    • Export Citation
  • 196

    Ernst A, Eberhardt R, Krasnik M, Herth FJ. Efficacy of endobronchial ultrasound-guided transbronchial needle aspiration of hilar lymph nodes for diagnosing and staging cancer. J Thorac Oncol 2009;4:947950.

    • Search Google Scholar
    • Export Citation
  • 197

    Rintoul RC, Tournoy KG, El Daly H. EBUS-TBNA for the clarification of PET positive intra-thoracic lymph nodes-an international multi-centre experience. J Thorac Oncol 2009;4:4448.

    • Search Google Scholar
    • Export Citation
  • 198

    Medford AR, Bennett JA, Free CM, Agrawal S. Mediastinal staging procedures in lung cancer: EBUS, TBNA and mediastinoscopy. Curr Opin Pulm Med 2009;15:334342.

    • Search Google Scholar
    • Export Citation
  • 199

    Mayr NA, Hussey DH, Yuh WT. Cost-effectiveness of high-contrast-dose MR screening of asymptomatic brain metastasis. AJNR Am J Neuroradiol 1995;16:215217.

    • Search Google Scholar
    • Export Citation
  • 200

    Nakagawa T, Okumura N, Miyoshi K. Prognostic factors in patients with ipsilateral pulmonary metastasis from non-small cell lung cancer. Eur J Cardiothorac Surg 2005;28:635639.

    • Search Google Scholar
    • Export Citation
  • 201

    Lee JG, Lee CY, Kim DJ. Non-small cell lung cancer with ipsilateral pulmonary metastases: prognosis analysis and staging assessment. Eur J Cardiothorac Surg 2008;33:480484.

    • Search Google Scholar
    • Export Citation
  • 202

    Oliaro A, Filosso PL, Cavallo A. The significance of intrapulmonary metastasis in non-small cell lung cancer: upstaging or downstaging? A re-appraisal for the next TNM staging system. Eur J Cardiothorac Surg 2008;34:438443; discussion 443.

    • Search Google Scholar
    • Export Citation
  • 203

    Decker DA, Dines DE, Payne WS. The significance of a cytologically negative pleural effusion in bronchogenic carcinoma. Chest 1978;74:640642.

    • Search Google Scholar
    • Export Citation
  • 204

    Burt M, Wronski M, Arbit E, Galicich JH. Resection of brain metastases from non-small-cell lung carcinoma. Results of therapy. Memorial Sloan-Kettering Cancer Center Thoracic Surgical Staff. J Thorac Cardiovasc Surg 1992;103:399410; discussion 410–391.

    • Search Google Scholar
    • Export Citation
  • 205

    Mehta MP, Tsao MN, Whelan TJ. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 2005;63:3746.

    • Search Google Scholar
    • Export Citation
  • 206

    Alexander E 3rd, Moriarty TM, Davis RB. Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases. J Natl Cancer Inst 1995;87:3440.

    • Search Google Scholar
    • Export Citation
  • 207

    Raviv G, Klein E, Yellin A. Surgical treatment of solitary adrenal metastases from lung carcinoma. J Surg Oncol 1990;43:123124.

  • 208

    Reyes L, Parvez Z, Nemoto T. Adrenalectomy for adrenal metastasis from lung carcinoma. J Surg Oncol 1990;44:3234.

  • 209

    Gelb AF, Tashkin DP, Epstein JD. Physiologic characteristics of malignant unilateral main-stem bronchial obstruction. Diagnosis and Nd-YAG laser treatment. Am Rev Respir Dis 1988;138:13821385.

    • Search Google Scholar
    • Export Citation
  • 210

    Henry DH, Costa L, Goldwasser F. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:11251132.

    • Search Google Scholar
    • Export Citation
  • 211

    Rosen LS, Gordon D, Tchekmedyian NS. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004;100:26132621.

    • Search Google Scholar
    • Export Citation
  • 212

    Henry DH, von Moos R, Hungria V. Delaying skeletal-related events in a randomized phase III study of denosumab versus zoledronic acid in patients with advanced cancer [abstract]. J Clin Oncol 2010;28(Suppl 15):Abstract 9133.

    • Search Google Scholar
    • Export Citation
  • 213

    Ibrahim A, Scher N, Williams G. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin Cancer Res 2003;9:23942399.

    • Search Google Scholar
    • Export Citation
  • 214

    Sakuma Y, Matsukuma S, Yoshihara M. Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations. Am J Clin Pathol 2007;128:100108.

    • Search Google Scholar
    • Export Citation
  • 215

    Forbes SA, Bhamra G, Bamford S. The catalogue of somatic mutations in cancer (COSMIC). Curr Protoc Hum Genet 2008;Chapter 10:Unit 10.11.

  • 216

    Lee SY, Kim MJ, Jin G. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers. J Thorac Oncol 2010;5:17341740.

    • Search Google Scholar
    • Export Citation
  • 217

    Sandler A, Yi J, Dahlberg S. Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer. J Thorac Oncol 2010;5:14161423.

    • Search Google Scholar
    • Export Citation
  • 218

    Socinski MA, Langer CJ, Huang JE. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol 2009;27:52555261.

    • Search Google Scholar
    • Export Citation
  • 219

    Johnson DH, Fehrenbacher L, Novotny WF. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:21842191.

    • Search Google Scholar
    • Export Citation
  • 220

    Reck M, von Pawel J, Zatloukal P. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:12271234.

    • Search Google Scholar
    • Export Citation
  • 221

    Mezger J, von Pawel J, Reck M. Bevacizumab (Bv) single-agent maintenance following Bv-based chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): results from an exploratory analysis of the AVAiL study [abstract]. J Clin Oncol 2009;27(Suppl 15):Abstract e19001.

    • Search Google Scholar
    • Export Citation
  • 222

    Scagliotti G, Brodowicz T, Shepherd FA. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol 2011;6:6470.

    • Search Google Scholar
    • Export Citation
  • 223

    Socinski MA, Schell MJ, Peterman A. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 2002;20:13351343.

    • Search Google Scholar
    • Export Citation
  • 224

    Soon YY, Stockler MR, Askie LM, Boyer MJ. Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol 2009;27:32773283.

    • Search Google Scholar
    • Export Citation
  • 225

    Riely GJ, Kris MG, Zhao B. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 2007;13:51505155.

    • Search Google Scholar
    • Export Citation
  • 226

    von Minckwitz G, du Bois A, Schmidt M. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol 2009;27:19992006.

    • Search Google Scholar
    • Export Citation
  • 227

    Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 2009;10:281289.

    • Search Google Scholar
    • Export Citation
  • 228

    Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009;28 Suppl 1:S2431.

    • Search Google Scholar
    • Export Citation
  • 229

    Fossella FV, DeVore R, Kerr RN. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:23542362.

    • Search Google Scholar
    • Export Citation
  • 230

    Shepherd FA, Dancey J, Ramlau R. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:20952103.

    • Search Google Scholar
    • Export Citation
  • 231

    Hanna N, Shepherd FA, Fossella FV. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:15891597.

    • Search Google Scholar
    • Export Citation
  • 232

    Shepherd FA, Rodrigues Pereira J, Ciuleanu T. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123132.

  • 233

    Demarinis F, Paul S, Hanna N. Survival update for the phase III study of pemetrexed vs docetaxel in non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2006;24(Suppl 18):Abstract 7133.

    • Search Google Scholar
    • Export Citation
  • 234

    Ramlau R, Gervais R, Krzakowski M. Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer. J Clin Oncol 2006;24:28002807.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 908 605 38
PDF Downloads 192 149 14
EPUB Downloads 0 0 0